Kiniksa Pharmaceuticals has received a consensus "Buy" rating from six analysts, with a price target of $37.17. Recent insider trading saw CFO Mark Ragosa and COO Eben Tessari sell shares, while institutional investors, including Charles Schwab, increased their holdings. The company reported a revenue increase of 46.9% year-over-year, despite missing EPS estimates.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.